Search


  Advanced Search
 
Popular Authors
No popular authors found.
 
 »  Home  »  Infectious Diseases  »  AirInSpace Raises $8.5 Million (EUR 6 Million) in VC Financing to Expand International Market Penetration for Biodecontamination Devices Providing Elimination of Deadly Airborne Microorganisms: "Our one-of-a-kind technology platform is designed
AirInSpace Raises $8.5 Million (EUR 6 Million) in VC Financing to Expand International Market Penetration for Biodecontamination Devices Providing Elimination of Deadly Airborne Microorganisms: "Our one-of-a-kind technology platform is designed
By Medicalread Staff | Published  06/3/2008 | Infectious Diseases | Unrated
AirInSpace Raises $8.5 Million (EUR 6 Million) in VC Financing to Expand International Market Penetr

ATLANTA & PARIS (Business Wire EON) October 8, 2007 --AirInSpace, the leadingsupplier of mobile ‘catch and kill’bioprotection devices in the French medical market, announced today thatit has closed on an $8.5 million (€6 million)Series “B” round offinancing.

The round was led by Matignon Technologies II FCPR with Oddo AM (throughFCPI GénérationsFutures) as a second investor. Aelios Finance served as financialadvisor for the company.

“This financing not only provides keyfinancial resources to fuel our company’sgrowth in the United States, Asia and Europe but also brings additionalinvaluable industry experience to our board of directors,”said Laurent Fullana, CEO of AirInSpace. “Weare now in a position to ramp up international sales and support morehospitals all over the world with new technology that ensures safe airfor better health.”

AirInSpace’s one-of-a-kind technology cansignificantly reduce airborne microbial contaminants. The technologyinitially stems from research aimed at protecting Russian cosmonauts andequipment in spacecraft. Working with several world-renownedlaboratories, AirInSpace has shown that its plasma-based air treatmenttechnology eliminates a wide range of microorganisms, including: Vacciniavirus (smallpox surrogate), Avian flu virus (H5N2), Aspergillus niger(common food contaminant), Staphylococcus aureus (agent ofsepticemia, Toxic shock syndrome, meningitis, endocarditis andpneumonia), Serratia marcescens (agent of urinary tract and woundinfections). The outstanding inactivation and germicidal effects of thetechnology have been proven even against one of the world’smost resistant microorganisms: e.g., Bacillus atrophaeus spores(anthrax surrogate).

By adapting and optimizing its technology for air treatment inhealthcare facilities, AirInSpace has introduced a new line of productsthat lowers the levels of airborne pathogens in order to reduceincidences of nosocomial infections. Adding to increased protection,AirInSpace’s solutions are also morecost-effective and flexible than traditional air-treatment technologies.

AirInSpace’s flagship product is a mobileair-decontamination unit called Plasmair™.The Plasmair™’sperformance has been clinically proven to lower airborne biologicalloads and is now being used to combat nosocomial infection to protectpatients, staff and products in high-risk areas of more than 100hospitals and clinics throughout France, including hematology wards,ICUs, pharmacies and operating theaters.

Aircraft have also begun using this year a new BiologicalDecontamination Unit (BDU), based on AirInSpace technology andco-developed with an undisclosed strategic air transportation partner,to lower the risk of cross-contamination in the airline cabin andprotect passengers and crew from airborne contaminates. Once againhigher efficiency and operational savings are made possible through thenovelty of the AirInSpace technology platform.

“During our evaluation of the technology, wewere very impressed by the added value delivered by the technology,”said Dr. Thierry Chignon, Partner, Matignon Technologies. “Forexample, one hospital we interviewed had previously closed down oneoperating room that did not meet the air quality standards. In just afew days, a Plasmair unit was installed, and the operating room could beused again. The alternative for the hospital was to do massivereconstruction of its ventilation system that would have taken manymonths and cost much more.”

“AirInSpace offers a breakthrough technologyin the biodecontamination sector validated in the medical market throughextensive use by opinion leaders, international institutes and a growingbase of French hospitals,” said LaurentDumas-Crouzillac, Investment Manager at Oddo AM.

“We are determined to help AirInSpace expandits international footprint and supports reapplication opportunities inmarkets beyond professional healthcare, building on the successfulimplementation in air transportation,” addedOddo AM Investment Manager Laetitia Vuitton.

About AirInSpace

Created in 2002, the AirInSpace company offers an innovative range ofproducts and services to address the need for microbial decontaminationof air. AirInSpace is a fast-growing high-tech environmental companythat has been awarded several national and international innovationawards for its superior bioprotection solutions. Laurent Fullana, thecompany CEO, has experience in product development, product marketing,licensing and B-to-B partnerships in the industrial and consumer goodsmarkets, working for Procter&Gamble, Rhone Poulenc and Rhodia in Europeand the United States. He graduated from the Ecole Superieure dePhysique et Chimie Paris (MSc in Physics), obtained a MSc in IndustrialEngineering at Ecole Centrale Paris, and holds an MBA degree fromColumbia Business School. For more information, please see www.airinspace.com,or contact the company at: mail@airinspace.com.

About Matignon Technologies

Matignon Investissement et Gestion is a Paris-based independentmanagement company that manages four venture funds, including its newventure, Matignon Technologies II FCPR, one of the largest Europeanfunds dedicated primarily to medical technologies. For furtherinformation please see: www.matignon-gestion.fr.Contact: Dr Thierry Chignon, Tel. +33 1 53 53 98 16, tchignon@matignon-gestion.fr.

About Oddo et Cie

Oddo et Cie is the leading private French bank, with €310million of net banking income, over 800 staff members, €22billion of assets under management, and €77million euros of consolidated net income in 2006. Its five businesslines are capital markets, asset management, investment banking, privatebanking and fund custody. Contacts: Laurent Dumas-Crouzillac, Tel. + 331 44 51 82 72, ldumascrouzillac@oddo.fror Laetitia Vuitton, Tel. +33 1 44 51 86 47, lvuitton@oddo.fr.

About Aelios Finance

Aelios Finance is the leading French corporate finance advisory firmhelping entrepreneurs and mid-cap companies to complete successfulcapital raising, mergers & acquisitions, LBO and IPO. For furtherinformation: www.aeliosfinance.com.Aelios Finance is also the exclusive French office of the world'slargest network of M&A companies, M&A International Inc. For furtherinformation: www.mergers.net.

xmlns:dc="http://purl.org/dc/elements/1.1/"xmlns:trackback="http://madskills.com/public/xml/rss/module/trackback/">rdf:about="http://www.prweb.comhttp://www.prweb.com/releases/airinspace/technology/prweb559413.htm"dc:identifier="http://www.prweb.comhttp://www.prweb.com/releases/airinspace/technology/prweb559413.htm"trackback:ping="http://www.prweb.com/postback/pingpr.php/SGFsZi1QaWdnLUxvdmUtVGhpci1UaGlyLVplcm8=" />-->

Post Comment:Trackback URL: http://www.prweb.com/pingpr.php/SGFsZi1QaWdnLUxvdmUtVGhpci1UaGlyLVplcm8=

Comments